Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in
the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in …

This is one of a series of statements discussing the use of GI endoscopy in common clinical
situations. The Standards of Practice Committee of the American Society for Gastrointestinal …

Background & Aims Whether non-selective β-blockers can prevent decompensation of
cirrhosis warrants clarification. Carvedilol might be particularly effective since its intrinsic …

This guidance provides a data-supported approach to risk stratification, diagnosis, and
management of patients with cirrhosis and portal hypertension (PH). A guidance document …

1 ESGE recommends that patients with compensated advanced chronic liver disease
(ACLD; due to viruses, alcohol, and/or nonobese [BMI< 30 kg/m 2] nonalcoholic …

These updated guidelines on the management of variceal haemorrhage have been
commissioned by the Clinical Services and Standards Committee (CSSC) of the British …

Patients with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk
of bacterial infections that may further precipitate other liver decompensations including …

Objective Recent data have suggested that non-selective β-blockers (NSBB) are associated
with increased mortality in patients with cirrhosis and refractory ascites. However, other …

Non-selective betablockers (NSBBs) remain the cornerstone of medical treatment of portal
hypertension. The evidence for their efficacy to prevent variceal bleeding is derived from …

Bleeding from gastroesophageal varices is a serious complication in patients with liver
cirrhosis and portal hypertension. Although there has been significance improvement in the …